Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy CEL-SCI stock (CVM)

Buy CEL-SCI stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

CEL-SCI is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.

Our top picks for where to buy CEL-SCI stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy CEL-SCI stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CVM. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy CEL-SCI stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

CEL-SCI stock price (NYSE MKT: CVM)

Use our graph to track the performance of CVM stocks over time.

CEL-SCI shares at a glance

Information last updated 2024-07-21.
Latest market close$1.32
52-week range$1.04 - $3.23
50-day moving average $1.26
200-day moving average $1.94
Wall St. target price$7.73
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.63

Is it a good time to buy CEL-SCI stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CEL-SCI price performance over time

Historical closes compared with the close of $1.32 from 2024-07-19

1 week (2024-07-16) -12.00%
1 month (2024-06-21) 2.33%
3 months (2024-04-23) -10.20%
6 months (2024-01-23) -50.19%
1 year (2023-07-21) -32.99%
2 years (2022-07-22) -65.45%
3 years (2021-07-23) 7.68
5 years (2019-07-23) 6.17

CEL-SCI financials

Revenue TTM $28,558
Gross profit TTM $-25,355,346
Return on assets TTM -53.51%
Return on equity TTM -173.88%
Profit margin 0%
Book value $0.26
Market Capitalization $71.5 million

TTM: trailing 12 months

CEL-SCI share dividends

We're not expecting CEL-SCI to pay a dividend over the next 12 months.

Have CEL-SCI's shares ever split?

CEL-SCI's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.

CEL-SCI share price volatility

Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $1.04 up to $3.23. A popular way to gauge a stock's volatility is its "beta".

CVM.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 0.667. This would suggest that CEL-SCI's shares are less volatile than average (for this exchange).

CEL-SCI overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. .

Frequently asked questions

What percentage of CEL-SCI is owned by insiders or institutions?
Currently 3.314% of CEL-SCI shares are held by insiders and 14.289% by institutions.
When does the fiscal year end for CEL-SCI?
CEL-SCI's fiscal year ends in September.
Where is CEL-SCI based?
CEL-SCI's address is: 8229 Boone Boulevard, Vienna, VA, United States, 22182
What is CEL-SCI's ISIN number?
CEL-SCI's international securities identification number is: US1508376076
What is CEL-SCI's CUSIP number?
CEL-SCI's Committee on Uniform Securities Identification Procedures number is: 150837409

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site